Belgium-based IBA (Ion Beam Applications) is hawking its two-room proton therapy solution this week at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting as a smaller, lower-cost alternative to traditional proton therapy centers.
Belgium-based IBA (Ion Beam Applications) is hawking its two-room proton therapy solution this week at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting as a smaller, lower-cost alternative to traditional proton therapy centers. The IBA configuration, dubbed Proteus Nano, starkly contrasts the often two-story proton therapy centers that occupy as much as 100,000 square feet. The company is framing Proteus Nano as requiring a much smaller footprint and imposing a lower acquisition cost, while still providing the highly accelerated proton beams needed to kill cancer tumors.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.